A novel IRE1 kinase inhibitor for adjuvant glioblastoma treatment - Archive ouverte HAL Access content directly
Journal Articles Iscience Year : 2023

A novel IRE1 kinase inhibitor for adjuvant glioblastoma treatment


Inositol-requiring enzyme 1 (IRE1) is a major mediator of the unfolded protein response (UPR), which is activated upon endoplasmic reticulum (ER) stress. Tumor cells experience ER stress due to adverse microenvironmental cues, a stress overcome by relying on IRE1 signaling as an adaptive mechanism. Herein, we report the discovery of structurally new IRE1 inhibitors identified through the structural exploration of its kinase domain. Characterization in in vitro and in cellular models showed that they inhibit IRE1 signaling and sensitize glioblastoma (GB) cells to the standard chemotherapeutic, temozolomide (TMZ). Finally, we demonstrate that one of these inhibitors, Z4P, permeates the blood-brain barrier (BBB), inhibits GB growth, and prevents relapse in vivo when administered together with TMZ. The hit compound disclosed herein satisfies an unmet need for targeted, non-toxic IRE1 inhibitors and our results support the attractiveness of IRE1 as an adjuvant therapeutic target in GB.
Fichier principal
Vignette du fichier
hal-04120068.pdf (5.17 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-04120068 , version 1 (09-06-2023)



Diana Pelizzari Raymundo, Dimitrios Doultsinos, Raphaël Pineau, Chloé Sauzay, Thodoris Koutsandreas, et al.. A novel IRE1 kinase inhibitor for adjuvant glioblastoma treatment. Iscience, 2023, 26 (5), pp.106687. ⟨10.1016/j.isci.2023.106687⟩. ⟨hal-04120068⟩
30 View
1 Download



Gmail Facebook Twitter LinkedIn More